| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10897555 | Cancer Epidemiology | 2014 | 5 Pages |
Abstract
The hENT1 genetic polymorphism of hENT1 G-706C was associated with response to the gemcitabine-containing chemotherapy and prognosis of NSCLC. Moreover, assaying this SNP in blood cells may represent a valuable biomarker for individualized treatment for NSCLC patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Fenglei Wu, Jian Zhang, Nan Hu, Huiyu Wang, Tongpeng Xu, Yi Liu, Yitong Zheng,